ConductScience.org, home

Comparison · NCT04745832-sae

Rituximab Plus Zandelisib vs Rituximab Plus Chemotherapy: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Rituximab Plus Zandelisib vs Rituximab Plus Chemotherapy: serious adverse events. Trial comparisons, record NCT04745832-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04745832-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2930.1760.445wilson
Risk in group 20.1950.1020.34wilson
Risk difference, group 1 minus group 20.0976-0.08850.276newcombe hybrid score
Risk ratio, group 1 over group 21.50.6863.28log
Odds ratio, group 1 over group 21.710.6134.75log
Number needed to harm, for one more participant with a serious adverse event on Rituximab Plus Zandelisib than on Rituximab Plus Chemotherapy10.3from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Rituximab Plus Zandelisib
Rituximab plus Zandelisib for 6 cycles followed by Zandelisib for 20 cycles Zandelisib: Zandelisib 60 mg capsules taken daily for two cycles followed by intermittent schedule starting at Cycle 3 Rituximab: Rituximab IV 375 mg/m2 for 6 cycles~In the Rituximab plus Zandelisib arm, 41 subjects enrolled
1241EG000
Group 2Rituximab Plus Chemotherapy
Rituximab and Bendamustine or Rituximab with (CHOP) for 6 cycles Rituximab: Rituximab IV 375 mg/m2 for 6 cycles Bendamustine: Bendamustine IV 90 mg/m2 on Days 1 and 2 for 6 cycles CHOP: Cyclophosphamide, Vindcristine IV, and Prednisone daily orally~In the R-chemo arm 31 subjects were enrolled to R-B and 10 to R=CHOP
841EG001

Harm

What it counts
Total, serious adverse events
Time frame
The occurrence of adverse events was assessed for 1 year, 7 months

Source ClinicalTrials.gov

Trial

Title
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
NCT number
NCT04745832
Phases
PHASE3
Conditions
Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
Interventions
Zandelisib, Rituximab, Bendamustine, CHOP
Lead sponsor
MEI Pharma, Inc.
Results first posted
2023-12-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04745832-sae